Skip to main content
Log in

The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

We have studied the effects of quinidine on ECG intervals and on the pharmacokinetics of flecainide and its two metabolites in 6 healthy men in an open randomized crossover study. Flecainide acetate (150 mg) was given as a constant rate i. v. infusion over 30 min.

Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.41·kg−1), but significantly increased its half-life (8.8 vs 10.7 h). This was attributable to a reduction in total clearance (10.6 vs 8.1 ml·min−1·kg−1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml·min−1·kg−1). The excretion of the metabolites of flecainide over 48 h was significantly reduced.

These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml·min−1·kg−1).

The effects of flecainide on ECG intervals were not altered by quinidine.

Thus, quinidine tends to shift extensive metabolizer status for flecainide towards poor metabolizer status and may also alter its renal excretion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. The CAST Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412

    Google Scholar 

  2. Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M (1986) Pharmacodynamics and side effect of flecainide acetate. Clin Pharmacol Ther 40:101–107

    PubMed  Google Scholar 

  3. Eichelbaum M (1988) Genetic polymorphism of sparteine/debrisoquine oxidation. ISI Atlas of Science. Pharmacology 3:243–251

    Google Scholar 

  4. Gross AS, Mikus G, Fischer C, Eichelbaum M (1991) Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol 40:155–162

    PubMed  Google Scholar 

  5. Haefeli WE, Bargetzi MJ, Follath F, Meyer UA (1990) Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 15:776–779

    PubMed  Google Scholar 

  6. Brøsen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239

    PubMed  Google Scholar 

  7. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562–567

    PubMed  Google Scholar 

  8. Munafo A, Reymond-Michel G, Biollaz J (1990) Altered flecainide disposition in healthy volunteers taking quinine. Eur J Clin Pharmacol 38:269–273

    PubMed  Google Scholar 

  9. Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treatment. Br J Clin Pharmacol 22:194–197

    PubMed  Google Scholar 

  10. Nielsen MD, Brosen K, Gram LF (1990) A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 29:299–304

    PubMed  Google Scholar 

  11. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine. Br J Clin Pharmacol 22:739–743

    PubMed  Google Scholar 

  12. Steiner E, Dumont E, Spina E, Dahlqvist R (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43:577–581

    PubMed  Google Scholar 

  13. Brøsen K, Gram LF (1989) Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 37:155–160

    PubMed  Google Scholar 

  14. Leemann TD, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers. Eur J Clin Pharmacol 29:739–741

    PubMed  Google Scholar 

  15. Desmeules J, Gascon M-P, Dayer P, Magistris M (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41:23–26

    PubMed  Google Scholar 

  16. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM (1989) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther 249:134–142

    PubMed  Google Scholar 

  17. Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative Odemethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624

    PubMed  Google Scholar 

  18. Munafo A, Biollaz J (1989) High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum. J Chromatogr 490:450–457

    PubMed  Google Scholar 

  19. Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8:7–20

    PubMed  Google Scholar 

  20. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson BS (1990) Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47:20–26

    PubMed  Google Scholar 

  21. Aronson JK, Carver JG (1981) Interaction of digoxin with quinidine. Lancet I:1418

    Google Scholar 

  22. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) Stereoseletive disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 28:555–566

    PubMed  Google Scholar 

  23. Kroemer HK, Turgeon J, Parker RA, Roden DM (1989) Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther 46:584–590

    PubMed  Google Scholar 

  24. Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53:41B-51B

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Munafo, A., Buclin, T., Tuto, D. et al. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur J Clin Pharmacol 43, 441–443 (1992). https://doi.org/10.1007/BF02220625

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02220625

Key words

Navigation